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PREDICTION OF TOTAL KNEE REPLACEMENT IN A 6-MONTH
MULTICENTRE CLINICAL TRILA WITH CHONDROITIN SULFATE IN KNEE
OSTEOARTHRITIS: RESULTS FROM A 4-YEAR OBSERVATION
J.-P. Raynauld 1, J. Martel-Pelletier 1, M. Dorais 2, F. Abram 3, B. Haraoui 1,
D. Choquette 1, F. Morin 4, L. Bessette 5, A. Beaulieu 6,
J.-P. Pelletier 1. 1Osteoarthritis Res. Unit, Univ. of Montreal Hosp. Res. Ctr.
(CRCHUM), Montreal, QC, Canada; 2 StatSci. Inc., Notre-Dame de l'Îlle-
Perrot, QC, Canada; 3 Imaging Res. & Dev., ArthroLab Inc., Montreal, QC,
Canada; 4Ctr. de recherche musculo-squelettique, Trois-Rivières, QC,
Canada; 5Groupe de Recherche en Rhumatologie et Maladies Osseuses,
Sainte-Foy, QC, Canada; 6 Faculty of Med., Université Laval, Sillery, QC, Canada
Purpose: To identify predictive factors for the incidence of total knee
replacement (TKR) during long-term follow-up of knee OA patients who
formerly received treatment with chondroitin sulfate (CS) or placebo in
a multicentre trial using clinical and quantitative magnetic resonance
imaging (qMRI) data.
Methods: Knee OA patients participating in a previous 6-month
randomized, double-blind controlled trial evaluating the impact of CS (400
mg b.i.d.; Condrosan, Bioibérica, Spain,) vs. placebo who had serial MRI
acquisitions of the symptomatic knee were recently contacted to evaluate
retrospectively the incidence of TKR of the study knee. A sub-group of
patients (n¼70) who had taken all the study medication and had all
clinical and MRI evaluations (according-to-protocol [ATP]) were selected
for this post-hoc retrospective analysis. Of this cohort 51 patients were
reachable for TKR incidence. The assessment was done blindly to treat-
ment allocation with a standardized phone interview.
Results: The patients’ mean age was 62.9 years, 61% were female and the
average BMI was 30.6 kg[[Unsupported Character - ∕]]m2. A total of 7 (6
target knees and 1 contralateral) TKRs (13.7%) were performed on this sub-
population in the timeframe of 3-4 years after completion of the original
study. Interestingly, there were more TKRs performed within the placebo
group (n¼5) than the CS group (n¼2) (71% vs. 29%, p¼0.15, logistic regres-
sion). The predictors of long-term TKRs for the target knee were investi-
gated by comparing the patients who had TKR (n¼6) of the target knee to
those who did not (n¼45), using data at baseline or the change at 1 year. At
baseline, the strongest predictors of TKR were WOMAC pain (p¼0.02,
logistic regression), stiffness (p¼0.01) and function (p¼0.04), bonemarrow
lesions of the medial tibial plateau (p¼0.03), and C reactive protein level
(p¼0.03). Changes at 1 year in medial cartilage volume (p¼0.05) and
WOMAC stiffness (p¼0.01) also predicted the occurrence of TKR.
Conclusions: These data demonstrate that, from a knee OA clinical trial, it
is possible to predict a “hard” outcome such as TKR using clinical and qMRI
data. Moreover, CS appeared to protect cartilage volume loss and improved
clinical parameters.
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COMPARISON OF ACETAMINOPHEN 1000 MG AND ACETAMINOPHEN
650 MG IN AN ACUTE PAIN MODEL: RESULTS FROM A RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY
D.S. Qi 1, L.G. May 2, B.A. Zimmerman 1, P.Y. Peng 1, E.O. Atillasoy 1,
S.N. Shelburne 3, G.H. Simmons 3, J.D. Brown 3, S.A. Cooper 4. 1McNeil
Consumer Hlth.care, Fort Washington, PA, USA; 2Consultant, Lock Haven,
PA, USA; 3 Jean Brown Res., Salt Lake City, UT, USA; 4Consultant, Palm
Beach Gardens, FL, USA
Purpose: Acetaminophen is recommended as a ﬁrst line treatment for
arthritis pain and 1000 mg is a widely used dose. The incremental beneﬁt
of acetaminophen 1000 mg versus 650 mg was questioned at a recent FDA
Advisory Committee Meeting. To answer this question, a randomized,
double-blind, placebo-controlled clinical trial was conducted to determine
whether acetaminophen 1000mgwasmore effective than acetaminophen
650 mg. The Dental Impaction Pain Model was chosen because of its
proven validity, assay sensitivity, reliability, and reproducibility. The
results from this model have been shown to be applicable to a wide variety
of pain modalities. The model is widely accepted and utilized to evaluate
dose-response and duration of effect of many prescription and over-the-
counter analgesics.Methods: Subjects were enrolled who required surgical extraction of up to
4 thirdmolars with aminimum requirement of 1 full bony or 2 partial bony
mandibular impactions. Subjects were randomly assigned a single dose of
acetaminophen 1000 mg, acetaminophen 650 mg, or placebo when they
had at least moderate pain and a Visual Analog Scale (VAS) score 50 out
of 100 mm post-surgically. Pain intensity and pain relief were measured
over 6 hours using a 100 mm VAS scale. Sum of Pain Intensity Difference
(SPID) and Total Pain Relief (TOTPAR) scores over 6 hours (SPRID6) was the
primary efﬁcacy endpoint. Other key efﬁcacy endpoints included Time to
Rescue analgesic, stopwatch Time to Conﬁrmed First Perceptible Relief and
Meaningful Relief, and Subject's Global Evaluation. Spontaneous adverse
events (AEs) were recorded throughout the study.
Results: All subjects (N¼540) completed the study and were included in efﬁ-
cacy and safety analyses. Demographic and baseline characteristics were
comparable among the 3 groups. Overall, the populationwas 52% female, age
16-30 years and 95% Caucasian. For the primary efﬁcacy endpoint, SPRID6,
acetaminophen 1000mg demonstrated a 24% improvement compared to 650
mg (529.4 vs 427.3; p¼0.001). Acetaminophen 1000mgwas also signiﬁcantly
superior to 650 mg (p0.002) for SPID6, TOTPAR6, Time to Rescue analgesic,
rescue rates through 4h (20% vs 32%) and 6h (29% vs 46%), and Subject Global
Evaluation (49% vs 34% with very good or excellent ratings). Both active
treatments were signiﬁcantly superior to placebo (p<0.001) for these efﬁcacy
endpoints. The 2 active treatments were similar for times to Conﬁrmed First
Perceptible andMeaningful Relief. AEswere reported by 18.5% of subjectswith
no clinically important difference among the 3 treatment groups. No serious
AEs were reported and no subjects discontinued due to an AE.
Conclusions: In this clinical trial, acetaminophen 1000 mg provided
clinically meaningful and statistically signiﬁcantly greater reduction in
pain intensity and greater pain relief compared with acetaminophen 650
mg and placebo. In addition, acetaminophen 1000 mg required less use of
rescue analgesic in treating acute pain compared with acetaminophen 650
mg and placebo. Signiﬁcantly superior efﬁcacy of acetaminophen 650 mg
was also demonstrated compared to placebo.
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A RETROSPECTIVE STUDY OF INTRA-ARTICULAR SODIUM
HYALURONATE (MW 500-730 KDA) INJECTION FOR TRAPEZIO-
METACARPAL JOINT OSTEOARTHRITIS
L. Frizziero 1, A. Frizziero 2, N. Giordan 3. 1Villa Toniolo, Bologna, Italy;
2Univerity of Padua, Padova, Italy; 3 Fidia Farmaceutici, Abano Terme, Italy
Purpose: Hand osteoarthritis (OA) is a highly prevalent disease, and TMCJ
is commonly targeted by OA. With respect to the long-term results, Hya-
luronic Acid (HA) seems to be the better alternative in the treatment of
TMCJ OA, even with a single injection. HA injections were found to be
effective in reducing pain and improving ﬁne hand function.
The purpose of this retrospective open-label study was to evaluate the
efﬁcacy and tolerability of i.a. injections of HA for the treatment of pain and
disability due to TMCJ OA. Data from the study were discussed based on
a review of the current news on the physiological effects of HA.
Methods: Fifty-eight patients, 50W(86.2%) and8M (13.8%), agedbetween40-
75ys, suffering fromTMCJOAandclassiﬁedasK-Lgrades2-3asper standardX-
ray, were included. The cases with known inﬂammatory arthritis, previous
thumb trauma and intra-articular (i.a.) injections with corticosteroids were
excluded. Primaryendpointswere:pain (VAS),NSAID intake, radial andpalmar
abduction of thumb (degrees), pinch strength (Kg/hand dynamometer).
Between Jan. 2000andDec. 2002 thepatients receivedan i.a. injectionof 0.8ml
of Hyaluronan saline, Hyalgan (10 mg/ml, MW 500-730 KDa)once weekly for
three consecutive weeks, using a dorsolateral approach. Control examinations
were carried out one, three and six months after the ﬁrst treatment.
Results: Intra-articular HA injections signiﬁcantly reduced spontaneous
and provoked pain and improved hand function and motion range in
comparison with baseline values. In particular after 1, 3 and 6 months
following the ﬁrst injection, the spontaneous and provoked pain revealed
a statistically signiﬁcant improvement (p<0,0001). In addition hand
functionality, in particular pinch strength, showed a signiﬁcant improve-
ment after the treatment. NSAIDs intake also evidenced a statistically
signiﬁcant reduction against baseline (p<0,017). The adverse events
occurring during the study (20.7%) are expected and related to local
symptoms such as pain during or following the HA administration.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S176Conclusions: This open-label study shows that i.a. HA injection for TMCJ
OA leads to a signiﬁcant improvement in all the investigated parameters,
which is still present after six months from baseline. There are currently
two broad categories proposed for the mechanism of action by which HA
may elicit short-and long-term pain relief: rheological or biomechanical
and biological (anti-inﬂammatory, anabolic, analgesic, chondroprotective
and anticatabolic) effects through interactions between HA and its
receptors CD44, RHAMM, ICAM-1. It is possible that one of the functions of
CD44 in stem cells may be to facilitate the endocytosis of HA which then
may act as a protector of their DNA from oxidants. Our study conﬁrms that
i.a. injections of HA in TMCJ are easily administered, and may give symp-
tomatic beneﬁt with minimal side effects.
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CHRONIC EFFECTS OF A FLEXIBLE AND MINIMALIST FOOTWEAR ON
CLINICAL, FUNCTIONAL AND GAIT BIOMECHANICAL ASPECTS IN THE
KNEE OSTEOARTHRITIS: A SINGLE-BLIND RANDOMIZED CLINICAL
TRIAL
F. Trombini-Souza, A. Matias, M. Yokota, C. Schainberg, R. Fuller,
I.C. Sacco. Univ. of Sao Paulo, Sao Paulo, Brazil
Purpose: Recent studies have shown that the acute use of shoes that
mimic barefoot gait decrease substantially knee loads while walking in
elderly with knee osteoarthritis (OA). Probably due to methodological
difﬁculties to implement this type of conservative treatment during
extended period, the effectiveness of minimalist footwear has not been
evaluated yet in elderly patients with knee OA. The purpose is to describe
a randomized clinical trial protocol for evaluating the therapeutic effect of
a minimalist (ﬂexible, non-heeled) and inexpensive footwear on clinical,
functional, and biomechanical gait in elderly women with knee OA.
Methods: Fifty six elderly womenwith knee OA grade 2 or 3 (Kellgren and
Lawrence) will be randomized in blocks and allocated in the intervention
group thatwill use aﬂexiblenon-heeled shoes -Moleca for at least 6hours
daily or in the control group, which could not use these shoes or be under
physical therapy or acupuncture treatment throughout these sis months.
The use of Paracetamol 500mg every six hour was allowed for both groups
in case of pain.Moleca (CalçadosBeiraRio S.A., NovoHamburgo, RS, Brazil)
is a women's double canvas ﬂexible ﬂat walking shoe without heels, with
a 5-mm anti-slip rubber sole and a 3-mm internal wedge of ethylene vinyl
acetate. The mean weight is 17219.6 g, ranging from 142 to 193 g
depending on the size. Both groups will be followed during 6months. They
will be assessed at baseline condition, after 3 months (intervention group)
and after 6months of baseline condition (end of intervention, both groups).
All the assessments will be performed by a physiotherapist that is blind to
which group the patientwas allocated. Themain outcome assessment is the
pain WOMAC score and the secondary outcomes are other WOMAC scores
pain assessment (visual analogue scale - VAS), Lequesne index, Six-Minute
Walk Test, and biomechanical gait analysis by means of 6 infrared cameras
and a multi-component force plate to determine the knee adduction
moment during gait. At baseline, all patients receive a diary to record the
hours of daily use of footwear intervention. Every two weeks, the same
physiotherapist carries phone calls to all patients in order to verify adher-
ence to treatment and the correctﬁlling this diary. The intergroupand inter-
moments will be performed by repeated measures analysis of variance
(a¼0.05). This Trial was approved by the local Ethics Committee and was
registered in ClinicalTrials.gov Identiﬁer: NCT01342458.
Results: Six hundred thirty-four elderly women have been contacted so far
and 20 have already been allocated in the intervention group (9) and in the
control (11). Five patients from intervention group have already completed
all 3 assessments and ﬁnished the protocol. The preliminary results have
shown that the elderly women of the intervention group have used the
Moleca shoe for an average monthly of 7 hours and 24 minutes ( 3:47),
corresponding to approximately 50% of the home-work hours of the day.
Conclusion: This is the ﬁrst randomized clinical trial protocol to assess the
chronic effect of a minimalist footwear on the clinical, functional and gait
biomechanics of elderly women with knee osteoarthritis. We expect that
the use of Moleca shoes for 6 months provides pain relief, reduction of
the knee adduction moment while walking and improves joint function in
elderly women with knee OA, and therefore can be considered as another
inexpensive option for conservative OA treatment.The authors are pleased to acknowledge the ﬁnancial support of State of
São Paulo Research Foundation - FAPESP (processes: 2011/01640-8, 2011/
03300-0, 2011/03069-6).
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RANDOMIZED, DOUBLE-BLIND CONTROL TRIAL OF PERI-ARTICULAR
HYALURONIC ACID:BOTULINUS TOXIN INJECTION IN LATERAL
EPICONDYLOSIS.
R.J. Petrella 1,2, J. Decaria 1, M. Petrella 1. 1U Western Ontario, London, ON,
Canada; 2 Lawson Hlth.Res. Inst., London, ON, Canada
Purpose: To compare and describe the effects of peri-articular hyaluronic
acid (HA) coadminsitered with botulinus toxin (Botox) versus placebo in
lateral epicondylosis.
Methods: 28 patients with elbow pain longer than two weeks and less
than 12 months, particularly exacerbated during resisted dorsiﬂexion of
thewrist with the elbow in full extensionwith a VAS score> 4.5 cm on a 0-
10 cm VAS were included. Assessments were done at baseline, days 7, 14,
30 and 90. Efﬁcacymeasures included patient's visual analogue scale (VAS)
of pain at rest (0-100 mm) and following assessment of grip strength (0-
100 mm). Grip strength was determined using a jamar hydraulic hand
dynamometer. Other assessments included patients’ global assessment of
elbow injury (5 point categorical scale; 1 ¼ no disability, 5 ¼ maximal
disability), patients’ assessment of normal function/activity (5 point
categorical scale), patients/physician satisfaction assessment (10 point
categorical scale), and adverse events as per WHO deﬁnition. Differences
between groups were determined using an intent-to-treat ANOVA. After
outcome assessment, patients were randomized to treatment with a single
injection of: HA + Botox (0.7 cc HA + 40 units Botox), HA alone (0.7 cc),
Botox (40 units), placebo (normal saline 0.7 cc). Injections were done free-
hand into the origin of the extensor carpi radialis brevis (ECRB).
Results: All patients completed the trial. Adverse events included pain and
swelling in one patient in the HA group at day 7 and ECRB weakness for 48
hours in one patient in the Botox group following injection. At 7 days,
a signiﬁcant improvement (p<0.05) from baseline and versus placebo in
VAS pain at rest and following grip testing was observed in all three
treatment groups. Grip strength was greater (p<0.05) for HA+Botox vs
other groups at 14, 30 and 90 days. Further, HA +Botox showed small but
signiﬁcant patient perception of normal function versus HA or Botox at one
month (p<0.05). However, at 90 days, HA+ Botox showed signiﬁcantly
(p<0.03) greater physician satisfaction versus all other groups. There were
no differences in patient global satisfaction between treatment groups at 7
or 90 days, but HA + Botox showed greater satisfaction at 14 and 30 days.
Conclusion: Peri-articular HA + Botox produced superior clinical and
statistical improvement in short- and long-term pain and function
compared to placebo and Ha or Botox alone with serious adverse effects.Epidemiology & Health Services Research
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HORMONE REPLACEMENT THERAPY PREVENTS FAILURE AFTER TOTAL
KNEE (TKA) AND HIP (THA) ARTHROPLASTY: A POPULATION-BASED
RETROSPECTIVE COHORT STUDY.
D. Prieto-Alhambra 1,2, M. Javaid 1, A. Judge 1, J. Maskell 3, C. Cooper 1,3,
N.K. Arden 1. 1Botnar Res. Ctr., Univ. of Oxford, Oxford, United Kingdom;
2 Inst. Català de la Salut-IDIAP Jordi Gol, Barcelona, Spain; 3MRC Lifecourse
Epidemiology; Southampton Univ., Southampton, United Kingdom
Purpose: Rates of primary total knee (TKA) and hip (THA) arthroplasties
are increasing worldwide. Together with patient reported outcomes,
implant survival is an important element in the evaluation of joint
replacement surgery. There is an urgent need to identify potential inter-
ventions to improve implant outcomes. Hormone replacement therapy
(HRT) might minimise osteolysis and loosening through its anti-resorptive
effects, and hence improve prosthesis survival.
